Our results suggest that progression of inflammation, hepatic fibrosis, and hepatic lipid metabolism disorder during NASH may influence the expression and scavenger functions of FcγRIIb in LSECs. This evidence concerns the gene FCGR2B and metabolic dysfunction-associated steatohepatitis.